Recent data regardingresponsiveness to combination and multiregiment chemotherapies may also provideinsight on the mechanism and activity of anti-EGFR therapies, specifically thatof the dual kinase inhibitor, Lapatinib (GW572016),which is capable of targeting both the EGFR and HER-2/neu tyrosine kinases thatare often overexpressed in breast cancer cells [4]. Here, ERBB2 is linked to breast cancer.